进展期胃癌分子靶向治疗的研究进展-海南医学.pdfVIP

Hainan Med J, May 2014, Vol. 25, No. 9 海南医学2014年5月第25卷第9期 doi:10.3969/j.issn.1003-6350.2014.09.0509 ·综 述· 进展期胃癌分子靶向治疗的研究进展 张玮芳，彭大为 ( 中南大学湘雅医学院附属海口市人民医院肿瘤化疗科，海南 海口 570208) 【摘要】 胃癌是目前全球癌症死亡的第二大原因，早期诊断困难，传统的手术和放化疗治疗进展期胃癌的 有效率低。随着对肿瘤发病机制研究的不断深入，分子靶向治疗成为肿瘤治疗的发展趋势。这些靶向治疗策略 主要包括：HER2 单克隆抗体、表皮生长因子受体抑制剂、血管生成抑制剂、mTOR 抑制剂、细胞周期蛋白依赖性 激酶(CDKs)、基质金属蛋白酶(MMPS)抑制剂/c-Met 抑制剂/IGF-1R 抑制剂/HSP90 抑制剂等。本文就进展期胃癌 近年来分子靶向治疗的研究结果及相关进展做一综述。 【关键词】 胃癌；分子靶向治疗 【中图分类号】 R735.2 【文献标识码】A 【文章编号】 1003—6350（2014 ）09—1321—04 Researchprogressofmoleculartargetedtherapyforadvancedgastriccancer. ZHANGWei-fang,PENGDa-wei. DepartmentofOncology,HaikouMunicipalHospitalAffiliatedtoXiangyaSchoolofMedicine,CentralSouthUniversity, Haikou570208,Hainan,CHINA 【Abstract】 Gastric cancer (GC) is currently the second leading cause of cancer death worldwide, and early di- agnosis is difficult and the efficacy of surgery, radiotherapy and chemotherapy for advanced GC is poor. With the deep- ening of study on pathogenesis of tumor, molecular targeted therapy has become a trend for cancer therapy. These ther- apeutic strategies include targeting HER2 monoclonal antibody, EGFR signal transduction pathway, anti-angiogenesis, PI3k/Akt/mTOR pathway inhibitors, multityrosine kinase inhibitors, cyclin dependent kinase (CDK) inhibitors, matrix metalloproteinase inhibitors, c-Met inhibitors, IGF-1R inhibitors and HSP90 inhibitors. This article focuses on summa- rize the most recent the development of targeted therapy for advanced gastric cancer. 【Keywords】 Stomach neoplasms; Molecular targeted therapy 胃癌是最常见的恶性肿瘤之一，其发病率在世界 尼单药治疗进展期或转移性胃腺癌，临床反应率为